<DOC>
	<DOCNO>NCT01322269</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability three dose level HQK-1001 administer daily 26 week subject sickle cell disease .</brief_summary>
	<brief_title>A Study HQK-1001 Patients With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Established diagnosis SCD Males females 12 60 year age , inclusive At least 3 episode SCDrelated crisis complication 3 year prior screen OR 1 episode acute chest syndrome 5 year prior screen If receive hydroxyurea , must receive stable dose least 6 month prior screen If hydroxyurea treatment discontinue , least 3 month elapse since last dose If transfusion 4 month prior screen , HbA level &lt; 20 % screening Average initial two HbF level ≥ 2.0 % within ≤ 7 day prior initial dose HQK1001 . The two must obtain ≥ 24 hour apart Ability swallow tablet Able willing give inform consent assent ( applicable ) If subject woman childbearing potential ( WCBP ) , must negative serum pregnancy test within 7 day first dose HQK1001 If subject WCBP , must agree use effective form contraception within 7 day initial dose HQK1001 one month HQK1001 discontinuation Sexually active male subject ( WCBP partner ) must agree use latex condom ensure partner ( ) use effective form contraception In view Investigator , subject able willing comply necessary study procedure More 4 hospitalization acute sickle cell related event previous 12 month prior screen Pulmonary hypertension require oxygen therapy QTc &gt; 450 msec ( male ) 470 msec ( female ) screen ECG ( QT correct Fridericia 's formula ) Assigned regular transfusion program Use erythropoiesis stimulate agent within 90 day screen ALT &gt; 3x upper limit normal ( ULN ) Serum creatinine &gt; 1.2 mg/dL A serious , concurrent illness would limit ability complete comply study requirement An acute vasoocclusive event within 3 week prior screen Creatine phosphokinase ( CK ) &gt; 20 % ULN An acute illness ( e.g. , febrile , GI , respiratory ) within 72 hour prior screen History syncope , clinically significant dysrhythmias resuscitation sudden death Chronic opiate use , , view Investigator , could confound evaluation investigational drug Current abuse alcohol drug Received another investigational agent within 4 week 5 halflives , whichever longer , prior screen Currently pregnant breast feeding child Known infection HIV1 Infection hepatitis B hepatitis C , patient currently therapy place therapy trial</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>